Literature DB >> 8401504

Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus.

M Sanson1, C Marineau, C Desmaze, M Lutchman, M Ruttledge, C Baron, S Narod, O Delattre, G Lenoir, G Thomas.   

Abstract

Neurofibromatosis type 2 (NF2) is an autosomal dominant disease which predisposes to the development of schwannomas, meningiomas, ependymomas, and juvenile cataracts. The NF2 gene (NF2) has recently been isolated and maps to chromosome 22q12 between the loci D22S212 and D22S32. Deletion studies in sporadic and NF2 associated schwannomas and meningiomas, and the presence of inactivating mutations in NF2 in patients suggest that it acts as a tumor suppressor gene. A candidate meningioma gene (MEN) has also been isolated from the same interval. A new highly polymorphic (CA)n marker, D22S268, which maps very near to NF2, has allowed us to identify a kindred with three living affected individuals, where the disease is presumably caused by a large germline deletion. Fluorescence in situ hybridization and pulsed field gel electrophoresis confirm the presence of a 700kb deletion which includes the neurofilament heavy chain subunit gene locus (NEFH), D22S268, NF2 and the putative MEN gene. The absence of meningiomas in this pedigree raises doubts as to the existence of a separate MEN locus in this region. These results support the hypothesis that NF2 results from the inactivation of a tumor suppressor gene on chromosome 22q.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8401504     DOI: 10.1093/hmg/2.8.1215

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  9 in total

Review 1.  BAP1 mutations in high-grade meningioma: implications for patient care.

Authors:  Ganesh M Shankar; Sandro Santagata
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

2.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities.

Authors:  D M Parry; M M MacCollin; M I Kaiser-Kupfer; K Pulaski; H S Nicholson; M Bolesta; R Eldridge; J F Gusella
Journal:  Am J Hum Genet       Date:  1996-09       Impact factor: 11.025

Review 3.  Pathology of meningiomas.

Authors:  L A Langford
Journal:  J Neurooncol       Date:  1996-09       Impact factor: 4.130

4.  A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals.

Authors:  D Bourn; S A Carter; D G Evans; J Goodship; H Coakham; T Strachan
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

Review 5.  Microdeletion del(22)(q12.2) encompassing the facial development-associated gene, MN1 (meningioma 1) in a child with Pierre-Robin sequence (including cleft palate) and neurofibromatosis 2 (NF2): a case report and review of the literature.

Authors:  Tom B Davidson; Pedro A Sanchez-Lara; Linda M Randolph; Mark D Krieger; Shi-Qi Wu; Ashok Panigrahy; Hiroyuki Shimada; Anat Erdreich-Epstein
Journal:  BMC Med Genet       Date:  2012-03-22       Impact factor: 2.103

6.  Multivariate gene expression analysis reveals functional connectivity changes between normal/tumoral prostates.

Authors:  André Fujita; Luciana Rodrigues Gomes; João Ricardo Sato; Rui Yamaguchi; Carlos Eduardo Thomaz; Mari Cleide Sogayar; Satoru Miyano
Journal:  BMC Syst Biol       Date:  2008-12-05

7.  Characterization of 22q12 Microdeletions Causing Position Effect in Rare NF2 Patients with Complex Phenotypes.

Authors:  Viviana Tritto; Marica Eoli; Rosina Paterra; Serena Redaelli; Marco Moscatelli; Francesco Rusconi; Paola Riva
Journal:  Int J Mol Sci       Date:  2022-09-02       Impact factor: 6.208

Review 8.  Multifaceted microglia - key players in primary brain tumour heterogeneity.

Authors:  Lily Keane; Mathilde Cheray; Klas Blomgren; Bertrand Joseph
Journal:  Nat Rev Neurol       Date:  2021-03-10       Impact factor: 42.937

9.  Loss of heterozygosity on chromosome 22 in ovarian carcinoma is distal to and is not accompanied by mutations in NF2 at 22q12.

Authors:  P Englefield; W D Foulkes; I G Campbell
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.